{"entity":{"id":"progressive-disease","kind":"term","name":"Progressive disease and radiographic progression","aka":["progressive disease","progression","disease progression","radiographic progression","radiological progression","clinical progression","progressed","progressing","on progression","at progression","after progression","post-progression","upon progression","time of progression","pseudoprogression","pseudo-progression","hyperprogression","iRECIST","iUPD","iCPD","PSA progression","biochemical progression","molecular progression","ctDNA progression","oligoprogressive"],"tldr":"The point at which a cancer is judged to be growing again despite treatment, usually a 20% increase on scans or a new lesion (RECIST). It ends progression-free survival, usually triggers a change of treatment, and defines 'lines' of therapy.","summary":"Progression is assessed on scheduled scans (every 6-12 weeks in trials), so recorded progression dates depend on imaging frequency; blinded central review reduces investigator bias. Immunotherapy introduced pseudoprogression (apparent growth from immune infiltration before shrinkage), handled by iRECIST's 'unconfirmed progression' category, and hyperprogression (rapid acceleration in a minority). Molecular progression (rising ctDNA or PSA) precedes radiographic progression by months and is now used to trigger treatment switches in trials (SERENA-6). Oligoprogression, growth at one or a few sites while the rest is controlled, is treated with local therapy while continuing the systemic drug.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors"}],"tags":[],"related":["pfs","recist","complete-response-term","first-line","oligometastatic","ctdna"],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["serena-6"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Trials"},"route":"/terms/progressive-disease/","neighbours":{"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/"},{"id":"first-line","kind":"term","name":"Lines of therapy","route":"/terms/first-line/"},{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/"},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/"}],"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"trial":[{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/"}],"paper":[{"id":"paper-therasse-recist-jnci-2000","kind":"paper","name":"Therasse 2000: RECIST, the standard rules for measuring whether a tumour responds","route":"/key-papers/paper-therasse-recist-jnci-2000/"}]}}